Modeling lethal X-linked genetic disorders in pigs with ensured fertility

Hitomi Matsunari, Masahito Watanabe, Kazuaki Nakano, Shin Enosawa, Kazuhiro Umeyama, Ayuko Uchikura, Sayaka Yashima, Toru Fukuda, Nikolai Klymiuk, Mayuko Kurome, Barbara Kessler, Annegret Wunsch, Valeri Zakharchenko, Eckhard Wolf, Yutaka Hanazono, Masaki Nagaya, Akihiro Umezawa, Hiromitsu Nakauchi, and Hiroshi Nagashima

Genetically engineered pigs play an indispensable role in the study of rare monogenic diseases. Pigs harboring a gene responsible for a specific disease can be efficiently generated via somatic cell cloning. The generation of somatic cell-cloned pigs from male cells with mutation(s) in an X chromosomal gene is a reliable and straightforward method for reproducing X-linked genetic diseases (XLGDs) in pigs. However, the severe symptoms of XLGDs are often accompanied by impaired growth and reproductive disorders, which hinder the reproduction of these valuable model animals. Here, we generated unique chimeric boars composed of mutant cells harboring a lethal XLGD and normal cells. The chimeric boars exhibited the cured phenotype with fertility while carrying and transmitting the genotype of the XLGD. This unique reproduction system permits routine production of XLGD model pigs through the male-based breeding, thereby opening an avenue for translational research using disease model pigs.

Disease model animals developed via genetic engineering have played an indispensable role in the study of human monogenic diseases. In addition to various rodent models, genetically modified pigs have recently been generated as models for intractable hereditary diseases and rare genetic disorders (1, 2). Mutations in genes homologous to those responsible for such disorders have been reported to cause similar symptoms in pigs to those in human patients, while genetic mutations do not necessarily produce the same disease phenotype in rodents (1, 3, 4).

Methods involving somatic cell cloning are highly effective for generating pigs with genetic mutations (5), and this technique is commonly used due to the limited availability of porcine embryonic stem (ES)/induced pluripotent stem (iPS) cells with proven totipotency, i.e., chimera formation ability (6, 7). Nuclear transfer using male cells carrying mutation(s) in an X chromosomal gene enables the direct “cell-to-animal” generation of models for X-linked genetic diseases (XLGDs). In fact, feasible production of model pigs reproducing XLGDs such as severe combined immunodeficiency (SCID) (8, 9), Duchenne muscular dystrophy (DMD) (10), and hemophilia A (11) has been reported. Among these XLGD model pigs, severe symptoms starting at the neonatal or juvenile stage develop in many cases.

Male individuals congenitally exhibiting severe symptoms of XLGDs are prone to neonatal lethality, impaired growth, and reproductive disability, complicating the propagation of disease model animals (8–10). For instance, the DMD model pigs reported previously showed premature lethality (10). Thus, severe symptoms often hinder the distribution of valuable disease model pigs. However, this problem can be overcome by the cryopreservation of sperm, which enables extensive distribution and long-term storage of these valuable genetic resources. Therefore, in the present study, we developed a method for generating unique chimeric boars that carry the mutation responsible for an XLGD in both somatic and germ cells while maintaining competence for growth and reproduction.

We showed that complementation of a male cloned embryo carrying an X-linked mutation (XKOY) with normal female embryonic cells (XWTXWT) can give rise to a viable chimeric boar comprising both mutant and normal cells (XKOY XWTXWT). Normal XWTXWT cells compensated for the impaired function of XKOY cells in the tissues/organs of the chimeric pig. We demonstrated that induced chimerism rescued the lethal congenital symptoms of gene-knockout (KO) pigs for three types of XLGDs: ornithine transcarbamylase deficiency (OTCD, Online Mendelian Inheritance in Man (OMIM) no. 311250) (12, 13), SCID (OMIM no. 300400) (9), and DMD (OMIM no. 310200) (10). Chimerism induced in a gene-deficient embryo has been demonstrated to compensate for the traits of genetic disorders in rodents (14–16).

Chimeric pigs that had been directed to grow into fertile boars as a result of intersex chimerism (17, 18) were able to produce next-generation progeny carrying the mutation. Reproduction of the chimeric boars demonstrated that their germ cells were derived from the original cloned embryos harboring the lethal
XLDG trait and that the X chromosomes carrying the mutant genes were transmitted to progeny in a Mendelian fashion.

The present study demonstrates that fertile chimeric boars that latently carry an XLDG trait can transmit the disease-causing mutations to progeny and will thereby play a pivotal role in expanding the practical use of novel disease model pigs.

Results
Gene-Knockout Cloned Pigs Exhibiting X-Linked Disorders. In the present study, we used model pigs for three types of XLDGs: OTCD, SCID (9), and DMD (10). OTC-KO pigs, a model for a congenital metabolic disorder characterized by hyperammonemia, were newly developed in this study by means of genome editing and somatic cell cloning. Cloned pigs were generated via nuclear transfer of primary culture cells carrying a truncated OTC gene (5-bp deletion in exon 2, c.186–190delCTCTGA; Fig. S1). The cloned OTC-KO pigs exhibited high perinatal mortality (6/8) and severe neonatal OTCD symptoms (2/2), including hyperammonemia, high urine levels of orotic acid, tremors, and early postpartum mortality (Table 1 and Movie S1).

To produce cloned embryos and animals for the other two models, we used cell lines carrying the mutations IL2RG XKOY (9) and DMD XKOY (10), which were established in our previous studies. IL2RG-KO pigs exhibited SCID symptoms such as T and NK cell deficiency (8). These pigs are prone to systemic infection under conventional housing conditions and, therefore, rarely develop into fertile adults.

DMD-KO pigs exhibited progressive dystrophic changes in their skeletal muscles, accompanied by increased serum creatine kinase levels, impaired mobility, muscle weakness and a maximum life span of 3 mo, due to respiratory impairment (10). In addition, characteristic age-related proteome changes were apparent in this model (19).

Complementation of Gene-Knockout Cloned Pigs. Cloned embryos derived from the three types of XLDG model pigs were complemented (18) with normal embryonic cells to produce chimeric boars (Fig. 1A). First, cloned embryos generated from male OTC-KO cells were injected at the morula stage with blastomeres from female cloned morulae expressing the humanized Kusabira-Orange gene (hKO) to generate chimeric blastocysts (Fig. 1B and C). A total of four piglets, including two chimeras (OTC XKOY ↔ XWTXWT), were obtained after the transfer of 70 blastocysts to a recipient gilt (Table 2 and Table S1). The chimerism of the piglets was confirmed based on coat color (Fig. 1D) and genotyping (Fig. S2). The remaining two animals were nonchimeric males derived from OTC-KO embryos (Table 2 and Table S1).

The OTC XKOY ↔ XWTXWT chimera was born healthy, grew up normally with normal blood ammonia level (Fig. S3 A and B and Table S4), and was fertile after maturity. Mating of the chimeric boar with a total of seven WT females yielded 74 F1 offspring in 7 litters (pregnancy rate: 100%; Table S7). All but one of the female offspring exhibited an OTC XKOYXWT genotype, and the male siblings were all wild type. The cause of X chromosome deletion (XKOY) in one exceptional female was unknown (Table S7). These results indicated that the germ cells of the chimeric boar had arisen from the OTC XKOY cloned embryos, such that the X chromosomes harboring the mutant OTC were transmitted to the F1 progeny in a Mendelian fashion. We previously reported that a chimeric pig embryo composed of male and female embryonic cells developed into a fertile boar, yielding sperm exclusively from the male cells (17, 18).

Cloned embryos generated from the male IL2RG XKOY cells (light-brown coat color) were complemented with female WT cloned embryos (black coat color). The host IL2RG XKOY embryos at the morula stage were injected with morula blastomeres to produce chimeric blastocysts (Table S2). The transfer of 62 blastocysts to a recipient female gave rise to six male offspring, including two (33.3%) chimeras (IL2RG XKOY ↔ XWTXWT), which were confirmed based on coat color (Fig. 1A and Fig. S3C) and genotyping (Fig. S2). The four IL2RG-KO cloned males (Table 2) among the siblings exhibited the same SCID symptoms reported previously (9). The chimeric males were not physiologically aberrant (Table S5) and were confirmed via FACS analysis to possess a normal lymphocyte composition (Fig. 2A). Both chimeric males were grown into fertile boars and yielded F1 offspring after mating with WT females (Table S8). All of the F1 females exhibited the IL2RG XKOYXWT genotype, indicating that the germ cells of the chimeric boar originated from the IL2RG XKOY embryos and that the X chromosome carrying the mutant gene was transmitted to the F1 progeny in a Mendelian fashion, as observed in the case of the OTC XKOY ↔ XWTXWT chimera.

Cloned morulae derived from DMD XKOY cells (white coat color) were complemented with blastomeres from WT (black coat color) cloned morulae to generate chimeric blastocysts. Among five offspring obtained after the transfer of 76 blastocysts to a recipient gilt, three chimeric males were identified (Fig. 1A, Table 2, Fig. S2, and Table S3). The clone siblings included two DMD-KO males (Table 2 and Table S3). One of the chimeric males (#61) behaved normally and grew to sexual maturity (Fig. S3 A and D), although it showed mild symptoms of DMD, such as muscle weakness of the legs and shortness of breath after walking for a long time, as the pig grew (Movie S2). Testes were harvested from the chimeric male at 7 mo of age to cryopreserve epididymal sperm. The frozen sperm were capable of efficiently

Table 1. Phenotypic features of OTC XKOY (OTCD) pigs

| Data items                        | Founder OTC XKOY clones | F2 OTC XKOY        | F2 WT male siblings |
|----------------------------------|-------------------------|--------------------|---------------------|
| No. of animals obtained          |                         | 8*                 | 18†                 | 22‡                 |
| Average birth weight             |                         | 345 ± 9.19 [231–463]| 574 ± 101.0 [405–787]| 1,110 ± 343.3 [405–1,636]|
| [range], g                       |                         |                    |                     |                     |
| Blood ammonia                    | Day 0                   | 661.0 [421, 901]   | 651.5 ± 612.9 [160.6–1,690.3] | 86.7 ± 39.6 [31.5–117.6] |
| [range], μg/dL                   | Day 1                   | N/A                | 1922.4 ± 539.3 [1,131.9–2,662.8] | 66.1 ± 18.9 [61–108.4] |
| Urinary orotic acid              | Day 0                   | 0.427 [0.116, 0.738] | 27.92 ± 17.4 [7.612–46.926] | 0.317 ± 0.26 [0.19–0.731] |
| [range], μmol/mg Cre.           |                         |                    |                     |                     |

Data are presented as the mean ± SD. N/A, not applicable; Cre., creatinine.

*Blood ammonia and urinary orotic acid were measured in two live animals. Statistical comparisons with other groups were not performed due to the small number of animals.
†Blood ammonia and urinary orotic acid were measured in five and four live animals, respectively.
‡Blood ammonia and urinary orotic acid were measured in 11 and 3 selected animals, respectively.
§Values with different superscript within the same line differ significantly (P < 0.05).
producing blastocysts through in vitro fertilization. Transfer of the in vitro-fertilized blastocysts yielded 12 piglets, including 7 (58.3%) heterozygous mutant females (X^KO^X^WT^) and 5 (41.7%) WT males (Table S9). The other chimeric male (#62) exhibiting lower chimerism died at the age of 3 mo after showing impaired motility, accompanied by severe weakness of the leg muscles and constant shortness of breath (Movie S3). The DMD-KO cloned males among the siblings died by 5 wk of age, consistent with our previous study describing the phenotypes of the original DMD-KO clone pigs (Table S6). (*)

Phenotypic Features of the Chimeric Pigs Carrying the Mutant Gene.

In the OTC X^KO^Y ↔ X^WT^X^WT^ chimera, blood ammonia levels were maintained within the normal range throughout growth (Table S4), and the pig reached maturity by 7 mo of age. This pig retained normal reproductive ability at the age of 3.5 y.

The IL2RG X^KO^Y ↔ X^WT^X^WT^ boars displayed a normal lymphocyte composition after growing into adulthood (6 mo old, Fig. 2A). They appeared physiologically normal and remained healthy until up to 3 y of age under conventional rearing conditions, including vaccinations (Table S5). A surgical intervention for testis collection at 7 mo of age did not cause infection, indicating normal immunological function, even after sexual maturity.

Histological analysis of the tissues of the DMD X^KO^Y ↔ X^WT^X^WT^ chimera (#62) that died at 3 mo of age revealed that the proportion of WT cells was very limited (Fig. S4). The lower proportion of WT cells in this animal was supported by their coat color chimerism (Movie S3). The high proportion of mutant cells in the skeletal muscles and diaphragm was suspected to be the cause of this individual’s impaired motor function and breathing.

In contrast, the chimeric boar (#61) that grew to maturity was characterized by a higher proportion of WT cells in its tissues according to both its coat color chimerism (~40%; Fig. S3D) and histological analysis (Fig. 3). Therefore, the milder impairment of motor and respiratory function was likely due to a lower proportion of DMD-deficient cells in the tissues of this animal. However, blood creatine kinase (CK) levels in the chimeric boar (75,460 U/L) were comparable to those of DMD patients, suggesting progressive muscle degradation in this animal (Table S6).

Transmission of the Mutant Trait to Offspring. The X^KO^Y ↔ X^WT^X^WT^ chimeric boars transmitted the causal mutant gene of their respective XLGDs to all of the F_1 female progeny (Tables S7–S9). In general, the phenotypes of the female carriers rarely showed expression of the X-linked conditions. However, a very small proportion (2/33) of the OTC^+/− females sporadically expressed hyperammonemia, and some of these animals fell into comas and were killed for analysis. The onset dynamics of the OTC^+/− female pigs resembled those of female carriers of the mutant OTC gene in humans (20, 21).

Table 2. Production efficiency of live X^KO^Y ↔ X^WT^X^WT^ chimeric pigs via blastocyst complementation

| Model types | X^KO^Y ↔ X^WT^X^WT^ | X^KO^Y clone | X^WT^X^WT^ clone |
|-------------|---------------------|--------------|------------------|
| OTCD*       | 1 (1)               | 2            | 0                |
| SCID*       | 2                   | 4            | 0                |
| DMD*        | 2 (1)               | 2            | 0                |

Numbers in parentheses indicate additional stillborn chimeras.

*The offspring in one litter are indicated for each model.
All but one (6/7, 85.7%) of the IL2RG<sup>+/−</sup> F<sub>1</sub> females grew into healthy, fertile adults (Fig. S5 A and B). The cause of the sudden death of one animal at 2 mo of age was unknown.

**Repetition of Phenotypic Symptoms in F<sub>2</sub> Offspring.** The OTC<sup>+/−</sup> and IL2RG<sup>+/−</sup> F<sub>1</sub> females were mated with WT boars to produce F<sub>2</sub> progeny (Table 3 and Tables S10–S13). Half of the male and female F<sub>2</sub> progeny exhibited the X<sup>KO</sup>Y and X<sup>KO</sup>Y<sup>WT</sup> traits, respectively, indicating that the X chromosome with the KO locus was faithfully inherited by the F<sub>2</sub> progeny from the carrier female in a Mendelian fashion (Tables S10 and S12). Backcrossing of X<sup>KO</sup>Y<sup>WT</sup> females with the chimeric boar should theoretically yield X<sup>KO</sup>Y<sup>KO</sup> animals. In fact, IL2RG X<sup>KO</sup>Y<sup>WT</sup> females backcrossed with the IL2RG X<sup>KO</sup>Y ↔ X<sup>WT</sup>X<sup>WT</sup> chimeric boar gave birth to X<sup>KO</sup>X<sup>KO</sup>, X<sup>KO</sup>Y, and XY siblings in a single litter (Table S13). However, OTC X<sup>KO</sup>X<sup>KO</sup> animals were not obtained, indicating prenatal lethality of the homozygous KO trait (Table S11).

The OTC X<sup>KO</sup>Y and IL2RG X<sup>KO</sup>Y<sup>WT</sup> males in the F<sub>2</sub> progeny exhibited the same symptoms as the founder X<sup>KO</sup>Y cloned pigs. All of the OTC-KO F<sub>2</sub> males showed typical OTCD symptoms, including hyperammonemia, high urine levels of orotic acid, tremor, and neonatal death (Table 1 and Movie S1).

Flow cytometry analysis of blood samples from IL2RG-KO F<sub>2</sub> males revealed an absence of T and NK cells, as observed in the founder IL2RG-KO cloned pigs (Fig. 2A). Deficiency of the thymus was also confirmed through autopsy of full-term fetuses (Fig. 2B). The IL2RG-KO F<sub>2</sub> males were prone to infection and suffered from severe complex infections by 3 wk after birth (Fig. S5 C–E).

These data clearly demonstrated that X<sup>KO</sup>Y ↔ X<sup>WT</sup>X<sup>WT</sup> chimeric boars can serve as stud males to transmit X-linked mutant genes to progeny while also providing valuable mutation-bearing sperm for cryopreservation, thereby playing a pivotal role in the reliable propagation of XLGD models.

**Discussion**

Diverse types of disease model pigs have been generated in recent years following the development of genome-editing technologies (22–24). The direct injection of genome-editing molecules into zygotes (25–27) is a feasible strategy for generating genetically engineered pigs. This method cannot, however, exclude the birth of offspring with unfavorable mutations (25, 28, 29). This implies the production of unnecessary animals for research (Fig. S6), which should be avoided from an animal welfare point of view.

Alternatively, the production of gene KO pigs via nuclear transfer of somatic cells carrying a mutation in a specific gene is a reliable and efficient strategy (5, 29, 30). Using this method, animals with the most appropriate mutation type can be exclusively generated by analyzing nuclear donor cells before producing cloned offspring. The production of cloned pigs provides a proof of concept for the outcome of a targeted gene mutation in a straightforward fashion. However, the symptoms that appear in cloned gene KO pigs can be influenced by epigenetic dysregulation (31), which is prone to arise in cloned animals. In this regard, a cloned pig with a mutant disease-causing gene is often flawed as a disease model.

Thus, the generation of disease model pigs through somatic cell cloning (i.e., via asexual reproduction) implies one obvious drawback. In addition, disease model pigs should preferably be reproduced via practical and feasible procedures, such as natural mating, in vitro fertilization, and artificial insemination. Such sexual reproduction systems using a stud male or his sperm have proven highly efficient for proliferating valuable animals throughout the history of animal husbandry.

In the development of an XLGD model, however, it is difficult to generate a healthy, fertile boar (9, 10). Therefore, the generation of a fertile chimeric boar that produces germ cells carrying the mutation(s) responsible for an XLGD has significant implications for the production and promotion of disease model pigs. Cryopreserved sperm carrying the mutant gene enable on-demand reproduction of the models (Figs. S6), thereby easing the maintenance of valuable lines, compared with the cost of maintaining females with a heterozygous mutation (X<sup>KO</sup>W<sup>T</sup>). Furthermore, female germ cells (oocytes) of disease model pigs with juvenile/premature lethality may be produced by blastocyst complementation using NANOS<sub>3</sub>−/− host embryos, which are characterized by depletion of germ cells in the ovary (32).

In model pigs for XLGDs, somatic cell-cloned females with X<sup>KO</sup>Y<sup>WT</sup> mutations often exhibit lethal phenotypes similar to those of X<sup>KO</sup>Y males (8). This effect is ascribed to skewed X inactivation (33) in the cloned animals and, therefore, complicates the maintenance of cloned X<sup>KO</sup>Y<sup>WT</sup> females as founders of an XLGD model (8). In any case, maintaining a line of large...
animals such as pigs using females as breeding stock is too costly, regardless of the survivability of the $X^{\text{KO}}X^{\text{WT}}$ females (Fig. S6).

OTCD is the most common congenital urea cycle disorder in humans (12). Hyperammonemia in infants causes ataxia, lethargy, and death in severe cases. Furthermore, persistent hyperammonemia in a patient gives rise to intellectual impairment (12). Liver transplantation is the only available curative treatment for this disease. Hence, OTCD model pigs would be a useful research tool not only for developing treatments before liver transplantation but also for investigating novel medical technologies, such as regenerative therapies, to replace liver transplantation. Pathogenesis in women carrying a heterozygous $OTC$ mutation is also a clinically serious issue (12). Chimeric boars harboring $OTC$ X$^{\text{KO}}$Y germ cells allow the large-scale production of $X^{\text{KO}}X^{\text{WT}}$ progeny and will therefore have a significant impact on research on the etiology of mutation-carrying females.

X-linked SCID is the most common form of primary immunodeficiency, occurring in one of 50,000–100,000 human births (34–36). This disease is lethal without appropriate treatment, such as hematopoietic stem cell transplantation, due to severe infections, including opportunistic infections. Without appropriate treatment, affected individuals typically die in the first year of life (34, 35). SCID model pigs would be useful for developing therapies for this life-threatening disease. SCID pigs would also be valuable as a large animal model for transplantation studies involving human pluripotent stem cells (PSCs) and/or PSC-derived organoids. In the present study, we generated $X^{\text{KO}}X^{\text{KO}}$ progeny by mating a chimeric boar carrying $IL2RG$ X$^{\text{KO}}$Y germ cells with $IL2RG$ X$^{\text{KO}}$Y WT carrier females. The $X^{\text{KO}}X^{\text{KO}}$ females may serve as a SCID model.

DMD is the most common form of progressive muscular dystrophy, affecting ~1 in 3,000 boys (38). Patients exhibit progressive proximal muscle weakness of the legs and pelvis in infancy and degeneration of heart and respiratory muscles at a later age, which can cause death (39). Next-generation therapies, including gene editing, exon-skipping drugs, gene therapy, and cell transplantation therapy, are considered promising remedies for this disease (40–42). In this context, the establishment of an effective system for producing DMD model pigs using chimeric boars containing $DMD$ X$^{\text{KO}}$Y germ cells will have a significant impact.

In a previous study by our group (10), cloned DMD-KO pigs died by 3 mo of age. In the present study, the normal growth of the chimeric boar to adulthood proved that the chimerism induced by exogenous normal cells cured the muscle dysfunction of the DMD pig, at least to some extent. However, the insufficient recovery of muscle function in pigs with lower chimerism may suggest limitations of cell transplantation therapy for DMD.

In contrast, mdx mice exhibiting milder DMD symptoms have been rescued by systemic chimerism (15). The symptoms of the mdx mice were also improved via i.p. transplantation of encapsulated Sertoli cells (43). Pig models with more severe DMD symptoms are tremendously useful for developing feasible therapies. Rescuing embryos carrying lethal genetic mutations through the induction of chimerism using normal cells has been reported to give rise to individuals with normalized traits (14, 18, 44). For instance, injecting Rag-2-deficient mouse blastocysts with normal ES cells led to the generation of somatic chimeras with normal B and T lymphocytes (14). The hematopoietic phenotype of Pdx1-KO mice has also been rescued via chimerism using blastocysts injected with ES/iPS cells (44), and the lethal pancreatic trait of Pdx1-He4 transgenic pigs was shown to be complemented by chimerism with WT cells (18). In the present study, we demonstrated a state-of-the-art embryo technology that rescues the lethal traits of XLGD model pigs and enables the transmission of the mutant gene to subsequent progeny. This chimeric rescue technology, which enables sexual reproduction of mutant cloned pigs produced via asexual somatic cell nuclear transfer (SCNT), will play a pivotal role in expanding the practical applications of disease model pigs.

**Table 3.** Generation of F$_2$ progeny from $OTC$-X$^{\text{KO}}$X$^{\text{WT}}$ and $IL2RG$-X$^{\text{KO}}$X$^{\text{WT}}$ F$_1$ females

| $F_2$ females* | X$^{\text{KO}}Y$ | XY | X$^{\text{KO}}X$ | XX |
|----------------|-----------------|-----|-----------------|-----|
| OTC-X$^{\text{KO}}$X$^{\text{WT}}$ | 18 [22.5%] | 22 [27.5%] | 20 [25.0%] | 20 [25.0%] |
| IL2RG-X$^{\text{KO}}$X$^{\text{WT}}$ | 5 [16.7%] | 9 [30.0%] | 9 [30.0%] | 7 [23.3%] |

*Eight ($OTC$-X$^{\text{KO}}$X$^{\text{WT}}$) and three ($IL2RG$-X$^{\text{KO}}$X$^{\text{WT}}$) females were mated with WT boars.
Materials and Methods
Detailed description of TALEN design/preparation, OTC-KO cell preparation, mutation analysis, production of cloned embryos/pigs, chimera pig production by blastocyst complementation, and analysis of chimeric/clone pigs are provided in SI Materials and Methods.

Animal Care. All of the animal experiments performed in this study were approved by the Institutional Animal Care and Use Committee of Meiji University (IACUC11-0016, 12-0008, 14-0010, 15-0002, 15-0003).

Statistical Analysis. Statistical analyses were performed with SPSS software (version 23; IBM). Differences in proportional data between the two groups were analyzed with the chi-square test. Numeric data, including body weight and biochemical parameters, were analyzed with Student’s t test or Dunnett’s T3 test. The level of significance was set at P < 0.05.

ACKNOWLEDGMENTS. We thank H. Kadoi for help with maintenance of pigs and S. Takayanagi for experimental–technical assistance. This work was supported by grants from the Japan Science and Technology Agency (Exploratory Research for Advanced Technology (ERATO), Nakauchi Stem Cell and Organ Regeneration Project), the Japan Agency for Medical Research and Development [Leading Allied Research and Development Project (LEAP)–Generation of Functional Organs using Developmental Niche], the Ministry of Health Labour and Welfare of Japan, and Meiji University International Institute for Bio-Resource Research. The generation of the DMD pig model was funded by the Bayerische Forschungsförderstiftung and the Else Kröner–Fresenius Foundation.

1. Klymiuk N, et al. (2016) Tailored pig models for preclinical efficacy and safety testing of targeted therapies. Toxicol Pathol 44:346–357.
2. Rogers CS (2016) Genetically engineered livestock for biomedical models. Transgenic Res 25:345–359.
3. Guilbaud C, Saeed Z, Downey GP, Radzioch D (2007) Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 36:1–7.
4. Rogers CS, et al. (2008) Disruption of the CFP gene produces a model of cystic fibrosis in newborn pigs. Science 321:1837–1841.
5. Kurome M, Kessler B, Wurensch M, Nagashima H, Wolf E (2015) Nuclear transfer and transgenesis in the pig. Nuclear Reprogramming. Methods in Molecular Biology, eds Beaupain N, Jammes H, Jouneau A (Humana, New York), Vol 1222, pp 37–59.
6. Du X, et al. (2015) Barriers for deriving transgene-free pig iPSCs with epigenetic vectors. Stem Cells 33:3228–3328.
7. Hou DR, et al. (2016) Derivation of porcine embryonic stem-like cells from in vitro-produced blastocyst-stage embryos. Sci Rep 6:25838.
8. Suzuki S, et al. (2012) I2Zr gene-targeted severe combined immunodeficiency pigs. Cell Stem Cell 10:753–758.
9. Watanabe M, et al. (2013) Generation of interleukin-2 receptor gamma gene knockout pigs from somatic cells genetically modified by zinc finger nucleases encoding mRNA. PLoS One 8:e76478.
10. Klymiuk N, et al. (2016) Dystrophin-deficient pig models provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Hum Mol Genet 22:4368–4382.
11. Kashikawa Y, et al. (2012) Porcine model of hemophilia A. PLoS One 7:e49450.
12. Leonard JV (2006) Disorders of the urea cycle and related enzymes. Inborn Metabolic Diseases, eds Fernandes J, Saudubray J-M, van den Berghe G, Walter JH (Springer, Berlin), pp 263–272.
13. Yamaguchi S, Bralley LL, Morizono H, Bale AE, Tuchman M (2006) Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum Mutat 27:626–632.
14. Chen J, Lansford R, Stewart V, Young F, Alt FW (1993) RAG-2-deficient blastocyst complementation: An assay of gene function in lymphocyte development. Proc Natl Acad Sci USA 90:4526–4532.
15. Stillwell E, et al. (2009) Blastocyst injection of wild type embryonic stem cells induces global corrections in mdx mice. PLoS One 4:e4759.
16. Iotani A, Hatayama H, Kasade K, Ikawa M, Okabe M (2011) Formation of a thymus from rat ES cells in xenogeneic nude mouse—rat ES chimeras. Genes Cells 16:397–405.
17. Nagashima H, Giannakis C, Ashman R, Nottle MB (2004) Sex differentiation and germ cell production in chimeric pigs produced by nuclear cell injection into blastocysts. Biol Reprod 70:702–707.
18. Matsumura H, et al. (2013) Blastocyst complementation generates exogenous pancreas in vivo in apenogeneic cloned pigs. Proc Natl Acad Sci USA 110:4557–4562.
19. Fröhlich T, et al. (2016) Progressive muscle protein changes in a clinically relevant pig model of Duchenne muscular dystrophy. Sci Rep 6:33632.
20. Maestri NE, Lord C, Glynn M, Bale A, Brusilov SW (1998) The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency. Medicine (Baltimore) 77:389–397.
21. Yorifuji T, et al. (1998) X-inactivation pattern in the liver of a manifesting female with ornithine transcarbamylase deficiency. Clin Genet 54:349–353.
22. Whitelaw CB, Sheets TP, Lillico SG, Telugu BP (2016) Engineering large animal models of human disease. J Pathol 238:247–256.
23. Yao J, Jiang H, Zhao J (2016) Genome editing revolutionize the creation of genetically modified pigs for modeling human diseases. Hum Genet 135:1093–1105.
24. Watanabe M, Nagashima H (2017) Genome editing of pig. Genome Editing in Animals. Methods and Protocols, ed Hatada I (Humana, New York), Vol 1630, pp 121–139.
25. Hai T, Teng F, Guo R, Li W, Zhou Q (2014) One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. Cell Res 24:372–375.
26. Wang Y, et al. (2015) Efficient generation of gene-modified pigs via injection of zygote with Cas9/gRNA. Sci Rep 5:8256.
27. Park KE, et al. (2017) Targeted gene knock-in by CRISPR/Cas9 ribonucleoproteins in porcine zygotes. Sci Rep 7:42458.
28. Sato M, et al. (2015) Direct injection of CRISPR/Cas9-related mRNA into cytoplasm of parthenogenetically activated porcine oocytes causes frequent mosaicism for indel mutations. Int J Mol Sci 16:17838–17856.
29. Zhou X, et al. (2015) Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer. Cell Mol Life Sci 72:1175–1184.
30. Tan W, Proudfoot C, Lillico SG, Whitelaw CBA (2016) Gene targeting, genome editing: From Dolly to editors. Transgenic Res 25:273–287.
31. Zhao J, Whyte J, Prather RS (2010) Effect of epigenetic regulation during swine embryogenesis and on cloning by nuclear transfer. Cell Tissue Res 341:13–21.
32. Ideta A, et al. (2016) Generation of exogenous germ cells in the ovari of sterile NANO53-null beef cattle. Sci Rep 6:24983.
33. Senda S, et al. (2004) Skewed X-inactivation in cloned mice. Biochem Biophys Res Commun 321:38–44.
34. Buckley RH (2002) Primary immunodeficiency diseases: Disectors of the immune system. Immunol Rev 185:206–219.
35. Cavazana-Calvo M, Lagresle C, Hacein-Bey-Abina S, Fischer A (2005) Gene therapy for severe combined immunodeficiency. Annu Rev Med 56:585–602.
36. Fischer A, et al. (2005) Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev 203:98–109.
37. Liao W, Lin JX, Leonard WJ (2013) Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38:13–25.
38. Aartoma-Rus A, Ginjaar IL, Bushby K (2016) The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet 53:145–151.
39. Bushby K, et al.; DMD Care Considerations Working Group (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:71–93.
40. Fairclough RJ, Wood MJ, Davies KE (2013) Therapy for Duchenne muscular dystrophy: Renewed optimism from genetic approaches. Nat Rev Genet 14:373–378.
41. Nakamura A (2017) Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy. J Hum Genet 62:871–876.
42. Wang JZ, Wu P, Shi ZM, Xu YL, Liu ZJ (2017) The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD. Brain Dev 39:547–556.
43. Chiappaluli S, et al. (2016) Intraperitoneal injection of microencapsulated Sertoli cells restores muscle morphology and performance in dystrophic mice. Biomaterials 75:313–326.
44. Kobayashi T, et al. (2010) Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. Cell 142:787–799.